APLS provides further guidance on ‘sexually explicit’ material - WSFA
4 days ago • Google News
Apellis Pharmaceuticals Inc (APLS)
US$ 17.4899-0.29%
Price Chart
Key Statistics
Market Cap
$ 2.2B
P/E Ratio
0.00
Revenue (TTM)
$ 775.84M
Volume
2.85M
52W High
$ 43.99
52W Low
$ 16.65
Dividend Yield
0.00%
Beta
0.72
Technicals
50-Day MA
21.8526
200-Day MA
29.6115
52 Week High
43.99
52 Week Low
16.65
About APLS
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unm.
Employees
705
Headquarters
Waltham, MA
CEO
Dr. Cedric Francois M.D., Ph.D.
Latest News
Top Gainers
Symbol/Name
LTP
% Chg
Top Losers
Symbol/Name
LTP
% Chg